Member Info for Laura2022

I don't want to as you make valid points but the ongoing daily commentary is bemusing

Newuncle

You seem obsessed with this and vet little commentary on CPX ?

We understand your points made here

Icecool

Yes, the dice roll is for any positive news before early 2025

The Board has therefore launched a comprehensive review of the strategic options open to the Company. In addition to exploring available funding options, the review will consider a range of potential actions, including but not limited to a licensing or sale of Company assets - such as the EpiSwitch NST and EpiSwitch SCB tests - and a possible hive-off of the Company's US business into a separately funded entity.

Added a final amount this morning and will hopefully see where my 1.8p average gets me

Hopefully OBD can achieve some progress BEFORE the need for funding in Q1

A company called CLCO has just had an offer of £9mln and it laden with debt and no real business!!

PYC has to be worth multiples of the current £1.4mln

They are reporting their trades usually 4pm to 4.30pm and someone is buying g them

Be good to have some numbers

Tech's voting rights over the Company's ordinary shares are below 5% of the Company's total issued share capital.

This fits PYC perfectly given our backing by UK bodies such as ICR and CRUK and Innoovate

UK has a world-renowned scientific research base, a vibrant startup ecosystem, and a strong track record of innovation in sectors such as AI, fintech and digital health. To accommodate these firms, the UK should have a special listing route onto the LSE Main Market specifically for high-growth firms in emerging technology sectors. 

Yes Trench

That was also posted on AVCT and SAR board

I think it would be great for LSE to merge both markets and also the £1bln VC gund swoop in

You worry about MIRI LOTM which has been in very similar situation?

I need it !!...and now got my average down so far to 2p

My mistake, you can now

At 1.28p

Hello Oxmil

I agree, particularly as PYC is now funded

As Kimg H says , if our dosing app with DosemeRx can cut costs on the Docetaxel drug which currently has sales of $3bln the surely the tool alone should be worth ££mlns to PYC going fowrd

Also , with PYC likely to hit £600k+ for H1 ( still time to land more contracts before Dec 2024) and with new biostatistics offering then I don't think £10mln valuation for PYC (comapred to current £1.4mln) is too adventurous

They don't need funding for 3-5mths ( Q1 2025) so I'm happy to average down NU

Truro

Trench did a great summary

Also talk of a new £1BLN fund to invest in smaller companies (see SAR board)

https://www.londonstockexchange.com/news-article/PYC/imc-presentation-on-company-website-amendment/16715770

Fantastic Truro

Presentation now on website

Yes NU

Apologies for not knowing the full extent of previous experience

I agree

PYC/beyond blood have got a test launching this month at a fraction of cost and does smaller things AND more ( see PYC last night )